Company
Every investor coverage indicates participated in a round New Enterprise Associates raised.
Investors whose own portfolio pages list New Enterprise Associates, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Future Fund | its portfolio page ↗ |
Companies New Enterprise Associates acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming New Enterprise Associates. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ASX-listed biotech Peplin arranged a private placement of roughly US$24 million to advance its keratosis drug into Phase III testing, led by GBS Venture Partners with several existing shareholders also taking part.
NEA is reportedly raising close to $7bn split between an early-stage fund and a growth fund, abandoning its longtime single multistage fund approach, according to the piece.